Levodropropizine

Levodropropizine is a peripheral antitussive agent.

It is used in the treatment of dry cough

Levodropropizine is Rapidly absorbed from the gastrointestinal tract. Bioavailability: >75%. Time to peak plasma concentration: 0.75 hours (range: 0.25-2 hours).The Plasma protein binding: 11-14%and excreted Via urine (35% as unchanged drug and metabolites) with elimination half-life: 2.3 ± 0.5 hours.

Levodropropizine shows common side effects like Nausea, vomiting, diarrhoea, abdominal distress, heartburn

Levodropropizine is available in the form of syrup

Levodropropizine is available in India, Germany, Canada, Italy.

Levodropropizine, the (-)-(S)-isomer of dropropizine, is a cough suppressant with peripheral action. It decreases the excitability of tracheobronchial receptors thus suppressing the cough reflex.

Levodropropizine is available in the form of syrup.

Levodropropizine is indicated for use in the treatment of dry cough.

Levodropropizine is used to treat excessive coughing and respiratory blockages in the lungs that stimulate the coughing. It can be used by both adults and children. The dosage depends upon the age, weight, medical history of the patient, health conditions and the response to the therapy.Most of the drugs are contraindicated in patients who have suffered or are suffering from cardiac disorders, lungs or liver disorders or renal malfunctioning. In such cases, immense precaution is required in the determination of the dosage.

Levodropropizine is approved for use in the following clinical indications

Dry Cough

Cough

Adult: 60 mg up to tid at intervals of at least 6 hours. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).

Child: 2-12 years 1 mg/kg/dose up to tid at intervals of at least 6 hours. Max: 3 mg/kg daily. >12 years Same as adult dose. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).

Hepatic impairment: Severe: Contraindicated.

Levodropropizine is available in various strengths as 30mg/5ml.

Levodropropizine is available in the form of syrup.

This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

General warnings

Driving or Operating Machinery

This medicine may cause dizziness or drowsiness in some patients. It is advised that you do not perform any activities that require high mental alertness like driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Diabetes Mellitus

This medicine should be used with caution in patients with a known history of diabetes mellitus due to the increased risk of worsening of the patient's condition. Close monitoring of blood glucose levels, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Severe kidney Impairment

This medicine should be used with caution in patients suffering from severe kidney diseases due to the increased risk of severe adverse effects. Close monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Liver Diseases

This medicine is not recommended for use in patients suffering from severe liver impairment due to the increased risk of severe adverse effects. In patients suffering from mild to moderate liver impairment, close monitoring of liver functions tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Use in elderly

This medicine is not recommended for use in elderly patients aged 65 and above without the advice of a doctor due to the increased risk of severe side effects. Appropriate dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Pharmacodynamic

Levodropropizine, the (-)-(S)-isomer of dropropizine, is a cough suppressant with peripheral action. It decreases the excitability of tracheobronchial receptors thus suppressing the cough reflex.

Pharmacokinetics

• Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: >75%. Time to peak plasma concentration: 0.75 hours (range: 0.25-2 hours).
• Distribution: Plasma protein binding: 11-14%.
• Excretion: Via urine (35% as unchanged drug and metabolites). Elimination half-life: 2.3 ± 0.5 hours.

• https://www.rxlist.com/dopram-drug.htm
• https://www.mims.com/india/drug/info/Levodropropizine?type=full&mtype=generic
• https://go.drugbank.com/drugs/DB00561
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003846/